April 2016 in “Journal of Investigative Dermatology” Microneedle arrays deliver botulinum toxin effectively for sweat suppression, similar to injections.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
February 2026 in “Cureus” Ciclosporin can cause excessive hair growth even with testosterone blockers.
June 2025 in “Fayoum University Medical Journal/Fayoum University Medical Journal ” Minoxidil and botulinum toxin are equally effective for treating female hair loss.
November 2022 in “Journal of the Endocrine Society” The patient likely has Chrousos syndrome, a rare condition causing insensitivity to glucocorticoids, requiring high-dose dexamethasone treatment.
20 citations
,
July 1990 in “Clinical and experimental dermatology” Taking cyproterone acetate and ethinyl oestradiol for hair loss can lower vitamin B12 levels in women.
January 2017 in “Corpus Université Laval (Université Laval)” Dutasteride may protect brain cells in early Parkinson's, while progesterone helps neuron recovery.
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
Botulinum toxin-A injections in the scalp can reduce hair loss and promote new hair growth in men with certain types of baldness.
July 2023 in “International Journal of Molecular Sciences” Trapa bispinosa Roxb. extract may help reduce prostate size and cell growth in BPH.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.
5 citations
,
May 2018 in “European journal of pharmacology” Fesoterodine is effective and safe for elderly patients with overactive bladder.
99 citations
,
August 1998 in “Pain” Blocking GABA(A) receptors increases neuron sensitivity, showing GABA and glycine have different roles in pain.
3 citations
,
January 2006 in “Eclética Química” Three cost-effective methods accurately measure finasteride in pharmaceuticals, better than current techniques.
September 2024 in “Frontiers in Neuroendocrinology” 5-alpha reductase inhibitors may help protect the brain and gut in Parkinson's disease.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” A patient with a PLEC mutation has epidermolysis bullosa, muscular dystrophy, and myasthenia gravis, which improved with steroid treatment.
253 citations
,
April 2014 in “Drugs” Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
74 citations
,
February 2018 in “Journal of the American Academy of Dermatology”
October 2006 in “Eclética Química” Three methods accurately measure finasteride in tablets using dyes and bromate-bromide.
There is no cure for myotonic dystrophy type 1, so treatment focuses on managing symptoms and complications.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
Different botulinum toxin products and concentrations can effectively reduce sweating, itching, bladder pressure, hair loss, and muscle spasms.
2 citations
,
March 2022 in “Laboratory Animal Research” A mild botulinum toxin injection improved sperm production and movement in aging mice.
March 2005 in “European Urology Supplements”
May 2026 in “Drug Delivery and Translational Research” Nanocarriers with spironolactone and 2-deoxy-D-ribose may improve hair loss treatment by targeting hair follicles directly.
December 2022 in “Acta Ophthalmologica” Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.